New Cholesterol Injection Leqvio Shows Promise in Heart Care

A new cholesterol-lowering injection, known as Leqvio or inclisiran, developed by Novartis, has shown significant potential to enhance heart care. Recent trial data indicates that Leqvio enables patients to reach their cholesterol targets more effectively than traditional therapies, suggesting a shift in how high cholesterol may be managed.

Leqvio is administered as an injection twice a year, following an initial dose and another at three months. The latest findings from the V-DIFFERENCE trial reveal that this innovative treatment helped approximately 85% of participants achieve their cholesterol goals within 90 days. In comparison, only 31% of patients receiving a placebo injection met the same targets.

The trial involved 898 participants who received Leqvio alongside a specific high-intensity statin and personalized lipid-lowering therapies. A control group of 872 individuals received a placebo injection with the same statin treatment. This research highlights not only the effectiveness of Leqvio in reducing low-density lipoprotein cholesterol (LDL-C) but also its potential to improve patient outcomes without the common side effects associated with statins.

According to Ruchira Glaser, global head of the cardiovascular, renal, and metabolic development unit at Novartis, the findings underscore the company’s commitment to addressing significant cardiovascular challenges. She stated, “These results highlight the potential of Leqvio to transform cardiovascular care by improving meaningful patient outcomes.”

Moreover, the V-DIFFERENCE trial is notable for being the first to investigate Leqvio’s impact on muscle pain, a frequent side effect of statin therapy. The results indicated that patients receiving Leqvio were 43% less likely to experience muscle-related issues compared to those in the placebo group.

The significance of these findings was echoed by Ulf Landmesser, chairman of the department of cardiology at the German Heart Centre of Charite and Charite University Medicine Berlin. He remarked that the trial focused on patient outcomes, demonstrating effective options for lipid management in at-risk patients who often remain above recommended LDL-C levels.

Recent data from the NHS Health Survey for England indicates that the percentage of adults with raised cholesterol increased to 53% in 2022, up from 43% in 2019. This trend is more pronounced among women, with 56% affected compared to 49% of men.

The findings from the V-DIFFERENCE trial will be presented at the European Society of Cardiology (ESC) Congress in Madrid, providing a platform to further discuss the implications of Leqvio in the evolving landscape of heart care. As cardiovascular disease continues to pose significant health risks, innovations like Leqvio may play a crucial role in improving patient health outcomes globally.